Last updated: February 20, 2026
There are multiple suppliers globally manufacturing ifosfamide, a chemotherapeutic agent used primarily for testicular cancer, sarcoma, and certain lymphomas. These suppliers include both branded and generic pharmaceutical companies.
Major Suppliers and Manufacturers
| Company Name |
Country of Origin |
Manufacturing Status |
Notes |
| Sanofi (brand: Ifosfamide CSL) |
France |
Branded |
Original manufacturer with patents protecting certain formulations. |
| Hikma Pharmaceuticals |
UK |
Generic |
Produces generic formulations of ifosfamide. |
| Zhejiang Huahai Pharmaceutical |
China |
Generic |
Produces bulk active pharmaceutical ingredient (API). |
| Teva Pharmaceutical Industries |
Israel |
Generic |
Distributes generic ifosfamide in multiple markets. |
| Fresenius Kabi |
Germany |
Generic |
Offers sterile formulations for infusion. |
| Apotex |
Canada |
Generic |
Manufactures generic versions of ifosfamide. |
| Jiangsu Hengrui Medicine |
China |
Generic |
Produces API and finished dosage forms. |
API Production and Supply
Most suppliers provide the active pharmaceutical ingredient (API), which is then used by pharmaceutical manufacturers to produce finished dosage forms.
API Suppliers
- Zhejiang Huahai Pharmaceutical
- Jiangsu Hengrui Medicine
- Pfizer (historically, but currently limited to specific markets)
- WuXi AppTec
Formulation Suppliers
Manufacturers such as Fresenius Kabi and Hikma focus on sterile injectable formulations for hospital use.
Regulatory and Market Access
Suppliers must adhere to regulatory frameworks such as the US FDA, European EMA, and China's NMPA, affecting their authorization to sell in specific regions. Generic entrants often require bioequivalence data to secure regulatory approval.
Market Trends and Competitiveness
- The global demand for ifosfamide remains steady in oncology treatment.
- Patent expirations of branded formulations have increased generic competition.
- API manufacturing increasingly shifts to countries like China and India due to cost advantages.
Supply Chain Risks
- Quality control issues in API production have led to shortages.
- Regulatory delays can impede market entry.
- Political and trade restrictions impact supply, especially from Chinese manufacturers.
Summary
Multiple suppliers globally produce both API and finished formulations of ifosfamide. Major generic companies distribute in key markets, while branded options mainly stem from Sanofi. API manufacturing is concentrated in China and India, with stringent regulatory standards influencing market access.
Key Takeaways
- The major API producers are Zhejiang Huahai, Jiangsu Hengrui, and WuXi AppTec.
- Branded formulations primarily come from Sanofi, with generics from Hikma, Fresenius Kabi, and Apotex.
- Regulatory approval, quality assurance, and regional market access are critical factors affecting supply stability.
- Increasing global production shifts are driven by cost and regulatory factors.
- Supply chain disruptions can impact availability, especially in high-demand settings.
FAQs
-
Who are the leading suppliers of ifosfamide API?
Zhejiang Huahai, Jiangsu Hengrui, and WuXi AppTec are leading API producers globally.
-
Are there regional differences in suppliers?
Yes. China and India dominate API manufacturing, while Europe and North America focus on finished drug formulations.
-
What regulatory hurdles impact supplier operation?
Suppliers must meet standards set by bodies like the FDA, EMA, and NMPA, affecting market entry and continuation.
-
Is there a patent barrier for generic ifosfamide?
Many patents have expired, facilitating generic entry, but some formulations may still be protected.
-
What are supply chain risks to watch?
Quality issues in manufacturing, regulatory delays, and geopolitical factors can cause shortages or supply disruptions.
Sources:
[1] GlobalData. (2022). Oncology drug market analysis.
[2] U.S. Food and Drug Administration. (2023). Orange Book: Approved Drug Products.
[3] European Medicines Agency. (2023). Summary of Product Characteristics for Ifosfamide.
[4] IQVIA. (2022). Global API manufacturing overview.
[5] Richardson, et al. (2021). API supply chain resilience. Journal of Pharmaceutical Sciences.
